Skip to main content
editorial
. 2020 Mar 5;9(2):119–137. doi: 10.1159/000505189

Table 7.

Phase 1b GO30140 study (arm F): objective response [modified from 37]

IRF RECIST v1.1
Atezo + Beva (n = 60) Atezo (n = 59)
Confirmed ORR 12 (20%) (11–32) 10 (17%) (8–29)
CR 1 (2%) 3 (5%)
PR 11 (18%) 7 (12%)
SD 28 (47%) 19 (32%)
Non-CR/non-PD 0 1 (2%)
PD 17 (28%) 25 (42%)
DCR 40 (67%) 29 (49%)
Median DOR, months NE (NE) NE (3.7 to NE)

Median duration of follow-up: 6.6 months. Figures are presented as n (%) or n (%) (95% CI). IRF, independent review facility; Atezo, atezolizumab; Beva, bevacizumab; ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; DOR, duration of response; NE, not estimable.